Use of MenAfriVac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns. Guidance for immunization programme decision-makers and managers

Abstract

Using a controlled temperature chain (CTC), the MenAfriVac® meningitis A vaccine and its diluent can be removed from the 2°C to 8°C cold chain, immediately before use, for a single period of time not exceeding four days. During this period it can be stored, transported and administered at temperatures up to 40°C (but must be carefully monitored so as not exceed 40°C).
This document provides guidance for decision-makers (how to decide if a CTC is the right approach for your country) and for district/zone coordinators (how to plan and implement a CTC campaign)
THIS is not a stand-alone document and it should be used as a complement to the CTC vaccinator training guide and accompanying facilitator’s guide. These documents provide guidance on how to implement CTC practices and, together with the WHO’s existing Immunization in Practice guidance series, provide general immunization session planning information.

Citation

World Health Organization. Use of MenAfriVac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns. Guidance for immunization programme decision-makers and managers. (2013) 26 pp. [WHO/IVB/13.04]

Use of MenAfriVac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns. Guidance for immunization programme decision-makers and managers

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.